paclitaxel albumin (Abraxane)
following a resubmission considered under the end of life / orphan medicine process:
paclitaxel albumin (Abraxane®) is accepted for use within NHS Scotland.
Indication under review: in combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.
In a randomised, phase III, open-label study paclitaxel albumin plus gemcitabine treatment improved median overall survival by 1.8 months compared with gemcitabine alone.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
|Drug Name:||paclitaxel albumin (Abraxane)|
|SMC Drug ID:||968/14|
|Indication:||In combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.|
|Sub Category:||8.1 Cytotoxic drugs|
|Date Advice Published:||9 February 2015|
|paclitaxel albumin (Abraxane)||Full submission||9 June 2014|